


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I):



(I)

wherein:

R<sup>1</sup> represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms selected independently from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CO<sub>2</sub>R<sup>4</sup> or a group -K-L-M;

K represents O, NR<sup>12</sup> or a bond;

L represents C1 to 4 alkyl optionally further substituted by OH or OMe; or L represents a bond;

M represents NR<sup>13</sup>R<sup>14</sup> or OR<sup>15</sup>;

$R^{13}$  and  $R^{14}$  independently represent H or C1 to 4 alkyl; or the group  $-NR^{13}R^{14}$  together represents a saturated 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR<sup>16</sup>;

$R^{16}$  represents H, C1 to 4 alkyl or C2 to 4 alkanoyl;

$R^2$  represents a saturated or partially unsaturated 3 to 7 membered ring, optionally including 1 or 2 heteroatoms independently selected from O, N and S(O)<sub>n</sub> and optionally incorporating 1 or 2 carbonyl groups; and optionally substituted by halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, CHO, C2 to 4 alkanoyl, C1 to 4 alkylsulphonyl, CO<sub>2</sub>R<sup>5</sup>, C(Z)NR<sup>17</sup>R<sup>18</sup> or pyrrolidine-2,5-dione; said C1 to 4 alkylsulphonyl group being optionally further substituted by 1H-isoindole-1,3(2H)-dione;

Z represents O or S;

$R^{17}$  and  $R^{18}$  independently represent H or C1 to 4 alkyl; or the group  $-NR^{17}R^{18}$  together represents a saturated 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR<sup>19</sup>;

$R^3$  represents H, halogen, C1 to 4 alkyl, C1 to 4 alkoxy or cyano;

$R^4$ ,  $R^5$ ,  $R^{12}$ ,  $R^{15}$  and  $R^{19}$  independently represent H or C1 to 4 alkyl;

n represents an integer 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

2. (Original) A compound according to Claim 1 wherein  $R^3$  represents halogen or methyl.

3. (Currently amended) A compound according to Claim 1 ~~or Claim 2~~ wherein K represents O.

4. (Currently amended) A compound of formula (I), according to ~~any one of Claims 1 to 3~~ Claim 1, which is:

{3-[4-(5-chloro-3-cyclopropyl-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl)phenoxy]propyl} dimethylamine;  
{3-[4-(5-chloro-3-cyclohex-1-en-1-yl-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl)phenoxy]propyl} dimethylamine;  
*tert*-butyl 3-(2-{4-[3-(dimethylamino)propoxy]phenyl}-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)piperidine-1-carboxylate;  
2-(2-furyl)-5-methyl-3-piperidin-3-yl-1*H*-pyrrolo[2,3-*b*]pyridine;  
3-[2-(2-furyl)-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]piperidine-1-carboxamide;  
5-chloro-3-piperidin-4-yl-2-(1*H*-pyrrol-3-yl)-1*H*-pyrrolo[2,3-*b*]pyridine;  
*tert*-butyl 4-(5-chloro-2-{4-[3-(dimethylamino)propoxy]phenyl}-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)piperidine-1-carboxylate;  
{3-[4-(5-chloro-3-piperidin-4-yl-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl)phenoxy]propyl} dimethylamine;  
[3-(4-{5-chloro-3-[1-(methylsulfonyl)piperidin-4-yl]-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl}phenoxy)propyl]dimethylamine;  
4-(5-chloro-2-{4-[3-(dimethylamino)propoxy]phenyl}-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)piperidine-1-carbaldehyde;  
4-(5-chloro-2-{4-[3-(dimethylamino)propoxy]phenyl}-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)piperidine-1-carboxamide;  
3-(2-{4-[3-(dimethylamino)propoxy]phenyl}-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-*N,N*-dimethylpiperidine-1-carboxamide;  
3-(2-{4-[3-(dimethylamino)propoxy]phenyl}-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-*N*-isopropylpiperidine-1-carboxamide;  
dimethyl[3-(4-{5-methyl-3-[1-(pyrrolidin-1-ylcarbonyl)piperidin-3-yl]-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl}phenoxy)propyl]amine;

[3-(4-{3-[1-(isopropylsulfonyl)piperidin-3-yl]-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl}phenoxy)propyl)dimethylamine;  
(3-{4-[3-(1-acetylpiperidin-3-yl)-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl}phenoxy}propyl)dimethylamine;  
3-(2-{4-[3-(dimethylamino)propoxy]phenyl}-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-*N*-methylpiperidine-1-carbothioamide;  
2-(2-{[3-(2-{4-[3-(dimethylamino)propoxy]phenyl}-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)piperidin-1-yl]sulfonyl}ethyl)-1*H*-isoindole-1,3(2*H*)-dione;  
3-[3-(2-{4-[3-(dimethylamino)propoxy]phenyl}-5-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)piperidin-1-yl]pyrrolidine-2,5-dione;  
dimethyl[3-(4-{5-methyl-3-[1-(methylsulfonyl)piperidin-3-yl]-1*H*-pyrrolo[2,3-*b*]pyridin-2-yl}phenoxy)propyl]amine;  
5-bromo-2-(4-methoxy-phenyl)-3-piperazin-1-yl-1*H*-pyrrolo[2,3-*b*]pyridine;  
5-bromo-2-(4-methoxyphenyl)-3-(4-methylpiperazin-1-yl)-1*H*-pyrrolo[2,3-*b*]pyridine;  
4-[5-bromo-2-(4-methoxy-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester;  
5-bromo-2-phenyl-3-morpholin-4-yl-1*H*-pyrrolo[2,3-*b*]pyridine;  
5-bromo-3-(4-methanesulfonylpiperazin-1-yl)-2-(4-methoxy-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine;  
4-[5-bromo-2-(4-methoxy-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]-piperazine-1-carbaldehyde;  
or a pharmaceutically acceptable salt of any one thereof.

5. (Cancelled)

6. (Currently amended) A pharmaceutical formulation comprising a compound of formula (I), as defined in ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.

7. (Currently amended) A method of treating, or reducing the risk of, a human disease or condition in which inhibition of Itk kinase activity is beneficial which comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof.


8. (Cancelled)

9. (Currently amended) The ~~use~~ method according to ~~Claim 8~~ Claim 7 wherein the disease is asthma.

10. (Currently amended) The ~~use~~ method according to ~~Claim 8~~ Claim 7 wherein the disease is allergic rhinitis.


11. (Currently amended) A process for the preparation of a compound of formula (I), as defined in ~~any one of Claims 1 to 4~~ Claim 1, and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof, which comprises:

a) reaction of a compound of formula (II):



(II)


in which R<sup>3</sup> is as defined in Claim 1, with a compound of formula (III):



(III)

in which R<sup>1</sup> and R<sup>2</sup> are as defined in Claim 1; or

b) arylation of a compound of formula (IV)



(IV)

wherein R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1, with a boronic acid of formula R<sup>1</sup>-B(OH)<sub>2</sub> wherein R<sup>1</sup> is as defined in Claim 1;

and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.